The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion

OCT, a non-calcemic analogue of 1,25(OH)2D3 has been found to have a more potent activity than that of 1,25(OH)2D3 regarding cell differentiation and immunopotentiation activity, and to prolong the average life span of MRL/l mice. Recently, we found that OCT effectively suppressed the secretion and...

Full description

Saved in:
Bibliographic Details
Published inContributions to nephrology Vol. 91; p. 123
Main Authors Nishii, Y, Abe, J, Mori, T, Brown, A J, Dusso, A S, Finch, J, Lopez-Hilker, S, Morrissey, J, Slatopolsky, E
Format Journal Article
LanguageEnglish
Published Switzerland 1991
Subjects
Animals
Calcitriol - analogs & derivatives
Calcitriol - metabolism
Calcitriol - pharmacology
Cells, Cultured
Humans
Parathyroid Hormone - biosynthesis
Parathyroid Hormone - metabolism
Online AccessGet more information

Cover

More Information
Summary:OCT, a non-calcemic analogue of 1,25(OH)2D3 has been found to have a more potent activity than that of 1,25(OH)2D3 regarding cell differentiation and immunopotentiation activity, and to prolong the average life span of MRL/l mice. Recently, we found that OCT effectively suppressed the secretion and synthesis of PTH without inducing hypercalcemia. In primary cultures of bovine parathyroid cells, OCT was capable of suppressing PTH release in a dose-dependent manner. OCT was also active in vivo, and, like 1,25(OH)2D3, decreased the pre-pro(PTH) mRNA levels. In a group of rats with CRF, daily administration of OCT, 8 ng i.p. for 2 weeks returned PTH levels to normal without changes in serum calcium. Preliminary results in dogs with CRF indicated that after the administration of OCT 5 micrograms i.v., N-terminal PTH decreased by 76% without changes in Ca. In conclusion, OCT may provide a unique contribution to the treatment of secondary hyperparathyroidism.
ISSN:0302-5144